

Rec'd PCT/PTO 24 OCT 2005  
10/525726

#7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  VON DER KAMMER <i>et al.</i>  Appl. No.: 10/525,726 ( <i>U.S. Nat'l Phase of PCT/EP03/09437</i> )  I.A. Filing Date: August 26, 2003  For: <b>Diagnostic and Therapeutic Use of FOAP-13 Polynucleotides and Polypeptides for Neurodegenerative Diseases</b>	Confirmation No.: 3700  Art Unit: <i>To Be Assigned</i>  Examiner: <i>To Be Assigned</i>  Atty. Docket: 2335.0060001/SRL/KPQ
--	--

**Preliminary Amendment and Submission of Sequence Listing**

**Mail Stop PCT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

As discussed during Applicants' telephone conference with Ms. Charitta A. Burt of the United States Patent and Trademark Office (USPTO) on October 20, 2005, Applicants were informed by the Sequence Information Submission branch of the USPTO that the computer readable form of the sequence listing that Applicants submitted on February 28, 2005 was acceptable. Therefore, in response to the Notification of Missing Requirements Under 35 U.S.C. § 371 in the United States Designated/Elected Office (DO/EO/US), dated August 23, 2005, in the above identified matter, and in advance of prosecution, please amend the application as follows:

***In the Specification:***

Please insert the sequence listing submitted on February 28, 2005 (a paper copy of which is attached herewith) at the end of the application.